Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.46 USD | 0.00% | -10.77% | +41.98% |
Mar. 19 | North American Morning Briefing : Stock Futures -2- | DJ |
Mar. 14 | Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 412M |
---|---|---|---|---|---|
Net income 2024 * | -79M | Net income 2025 * | -144M | EV / Sales 2024 * | - |
Net cash position 2024 * | 182M | Net cash position 2025 * | 57.6M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.24
x | P/E ratio 2025 * |
-3.08
x | Employees | 42 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.66% |
Latest transcript on Larimar Therapeutics, Inc.
1 week | -10.77% | ||
Current month | -14.89% | ||
1 month | -20.15% | ||
3 months | +43.56% | ||
6 months | +129.08% | ||
Current year | +41.98% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 65 | - | |
Michael Celano
DFI | Director of Finance/CFO | 65 | 20-05-27 |
Noreen Scherer
CTO | Chief Tech/Sci/R&D Officer | - | 18-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jonathan Leff
BRD | Director/Board Member | 55 | 20-05-27 |
Frank Thomas
BRD | Director/Board Member | 54 | 20-05-27 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 23-10-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +2.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 6.46 | 0.00% | 222,439 |
24-04-23 | 6.46 | +0.94% | 243,953 |
24-04-22 | 6.4 | -1.99% | 238,190 |
24-04-19 | 6.53 | +2.35% | 509,318 |
24-04-18 | 6.38 | -9.50% | 510,792 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.98% | 412M | |
-1.51% | 105B | |
+3.22% | 97.5B | |
+1.86% | 22.19B | |
-16.53% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.09% | 14.52B | |
+5.47% | 14.09B | |
+28.85% | 10.99B |
- Stock Market
- Equities
- LRMR Stock